SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) produced a 54.75% rally since recording the worst price of $0.1. Thanks to the latest 10.49% increase, it now trades at $0.16. Throughout the trading on 7/26/2019, the share price floated between $0.145 and $0.179. This company shares are 5368.75% off its target price of $8.75 and the current market capitalization stands at $18.3M. The recent change has given its price a -53.05% deficit over SMA 50 and -93.58% deficit over its 52-week high. The stock witnessed 24.41% gains, -83.19% declines and -89.61% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SLS’s volatility during a week at 12.62% and during a month it has been found around 16.8%.

SELLAS Life Sciences Group, Inc. (SLS) Top Holders

Institutional investors currently hold around $1 million or 11.8% in SLS stock. Look at its top three institutional owners: Renaissance Technologies Llc owns $209 thousand in SELLAS Life Sciences Group, Inc., which represents roughly 1.14% of the company’s market cap and approximately 20.9% of the institutional ownership. Similar statistics are true for the second largest owner, 683 Capital Management, Llc, which owns 1,275,000 shares of the stock are valued at $201 thousand. The third largest holder is Vanguard Group Inc, which currently holds $116 thousand worth of this stock and that ownership represents nearly 0.63% of its market capitalization.

SELLAS Life Sciences Group, Inc. 13F Filings

At the end of March reporting period, 9 institutional holders increased their position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by some 250,026 shares, 15 decreased positions by 747,746 and 5 held positions by 2,653,295. That puts total institutional holdings at 3,651,067 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 33,932 shares while 9 institutional investors sold out their entire positions totaling 116,926 shares.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Insider Trades

Multiple company employees have indulged in significant insider trading. SELLAS Life Sciences Group, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Stergiou Angelos M. has sold 23,277 shares of SELLAS Life Sciences Group, Inc. (SLS) in the trading session dated Dec. 31, 2018. These shares are worth $29,096 and were traded at $1.25 each. The SEC filing shows that Nisi Rudolph performed a sale of 17 shares. The Director disposed these shares by way of transaction on Jun. 20, 2017. The company’s shares were given away at $16.5 per share worth to an income of some $275 to the account of Nisi Rudolph.

10% Owner, Hudson Bay Capital Management, sold 78,781 common shares of SELLAS Life Sciences Group, Inc. (SLS) in the open market. In a transaction dated Feb. 08, 2017, the shares were put up for sale at an average price of $25.2, raking in a sum of $1,985,271. After this sale, 67,885 common shares of SLS are directly owned by the insider, with total stake valued at $10,862.

In the transaction dated Jun. 01, 2016, a great number of shares sold came courtesy the Former CFO; Dunlap Ryan disposed a total of 211 shares at an average price of $1308.01, amounting to approximately $276,587. The insider now directly owns 31 shares worth $5.

SELLAS Life Sciences Group, Inc. (SLS) Analyst Guide

Several analysts have released their opinion on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].